Immunic, a late-stage biotech company, announced a virtual R&D day on September 9, 2026, focusing on its oral therapy vidofludimus calcium for relapsing multiple sclerosis (MS). The event will feature company executives and leading MS experts discussing the drug's potential to address neurodegenerative and inflammatory aspects of MS. Top-line data from Phase 3 ENSURE trials are expected by the end of 2026, which could advance treatment options beyond traditional anti-inflammatory drugs. Immunic also plans to start a Phase 3 trial for progressive MS later in 2026.
Harmony Biosciences announced that Peter Anastasiou will become President and CEO effective January 1, 2027, succeeding Jeffrey M. Dayno, who will retire at the end of 2026. Dayno will remain as a non-executive advisor through 2027 to support the com...
Zenas BioPharma presented new data on obexelimab at the 6th International Symposium on IgG4-Related Disease, highlighting sustained clinical activity in treating IgG4-RD. Phase 3 INDIGO open-label extension results showed a high probability of patien...
The St. Louis Blues and Gray Media announced a multi-year deal to broadcast 10 select Thursday games over-the-air on ABC 32 in St. Louis and 10 other markets during the 2026-27 NHL season. This expands access to Blues games for over 4.8 million house...
Fate Therapeutics has appointed Jamie Harrell as Senior Vice President of Market Development & Commercial Operations to spearhead the commercialization of its CAR T-cell therapies, including FT819 and FT839, targeting autoimmune diseases like lupus n...
Iridex Corporation announced a two-year clinical study demonstrating that MicroPulse transscleral laser therapy significantly reduces intraocular pressure (IOP) and medication use in patients with early to advanced glaucoma. The study, involving 84 e...
